会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明申请
    • Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
    • 四氮取代咪唑衍生物作为具有高CB1 / CB2受体亚型选择性的大麻素CB1受体调节剂
    • US20050267161A1
    • 2005-12-01
    • US11138289
    • 2005-05-27
    • Josephus LangeHenderik WalsCornelis Kruse
    • Josephus LangeHenderik WalsCornelis Kruse
    • A61K31/4178A61K31/4439C07D233/90C07D43/02
    • C07D233/90
    • The present invention relates to 1,2,4,5-tetrasubstituted imidazole derivatives as selective cannabinoid CB1 receptor modulators, in particular CB1 receptor antagonists or inverse agonists having a high CB1/CB2 receptor subtype selectivity, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said imidazole derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. A beneficial effect is disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. The invention also relates to the use of a compound of the invention for the manufacture of a medicament for treating or preventing a disease or condition. More particularly, the invention relates to a new use for the treatment of a disease or condition disclosed herein or apparent to a person skilled in the art from the specification and general knowledge in the art. In embodiments of the invention specific compounds disclosed herein are used for the manufacture of a medicament useful in the treatment of psychiatric and neurological disorders. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.
    • 本发明涉及作为选择性大麻素CB 1受体调节剂的1,2,4,5-四取代的咪唑衍生物,特别是CB 1受体拮抗剂或具有高 CB 1 / CB 2受体亚型选择性,制备这些化合物的方法和可用于合成所述咪唑衍生物的新型中间体。 本发明还涉及本文公开的化合物在制备产生有益效果的药物中的用途。 本领域技术人员从本领域的说明书和一般知识中可以公开有益效果或显而易见的。 本发明还涉及本发明化合物在制备用于治疗或预防疾病或病症的药物中的用途。 更具体地,本发明涉及本领域技术人员从本领域技术人员的说明书和一般知识中治疗本文公开的疾病或病症的新用途。 在本发明的实施方案中,本文公开的具体化合物用于制备用于治疗精神病和神经障碍的药物。 化合物具有通式(I),其中符号具有说明书中给出的含义。